- Home
- CATO vs IKNA Comparison
CATO vs IKNA Comparison
Compare CATO & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATO
- IKNA
- Stock Information
- Founded
- CATO 1946
- IKNA 2016
- Country
- CATO United States
- IKNA United States
- Employees
- CATO N/A
- IKNA N/A
- Industry
- CATO Clothing/Shoe/Accessory Stores
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- CATO Consumer Discretionary
- IKNA Health Care
- Exchange
- CATO Nasdaq
- IKNA Nasdaq
- Market Cap
- CATO 59.2M
- IKNA 63.7M
- IPO Year
- CATO N/A
- IKNA 2021
- Fundamental
- Price
- CATO $2.86
- IKNA $1.37
- Analyst Decision
- CATO
- IKNA Strong Buy
- Analyst Count
- CATO 0
- IKNA 1
- Target Price
- CATO N/A
- IKNA $4.00
- AVG Volume (30 Days)
- CATO 32.4K
- IKNA 63.1K
- Earning Date
- CATO 08-21-2025
- IKNA 08-07-2025
- Dividend Yield
- CATO 6.05%
- IKNA N/A
- EPS Growth
- CATO N/A
- IKNA N/A
- EPS
- CATO N/A
- IKNA N/A
- Revenue
- CATO $642,949,000.00
- IKNA N/A
- Revenue This Year
- CATO N/A
- IKNA N/A
- Revenue Next Year
- CATO N/A
- IKNA N/A
- P/E Ratio
- CATO N/A
- IKNA N/A
- Revenue Growth
- CATO N/A
- IKNA N/A
- 52 Week Low
- CATO $2.19
- IKNA $0.97
- 52 Week High
- CATO $6.70
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- CATO 64.69
- IKNA 55.10
- Support Level
- CATO $2.84
- IKNA $1.31
- Resistance Level
- CATO $3.05
- IKNA $1.42
- Average True Range (ATR)
- CATO 0.14
- IKNA 0.05
- MACD
- CATO 0.02
- IKNA -0.00
- Stochastic Oscillator
- CATO 100.00
- IKNA 51.24
About CATO Cato Corporation (The)
The Cato Corp operates as a specialty retailer of fashion apparel and accessories in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.